12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sufentanil NanoTab PCA System: Phase III data

Furthermore, the nurses who set up and managed the treatments in the trial reported significantly greater overall satisfaction (3.93 vs. 3.32 out of 5 points, p<0.001) and overall ease of care (4.26 vs. 3.82 points, p=0.018) with Sufentanil NanoTab compared to morphine. Patients also reported significantly greater overall satisfaction (4.15 vs. 3.83 points, p=0.003) and overall ease of care (4.45 vs. 4.07 points, p<0.001) with Sufentanil NanoTab compared to morphine. AcelRx expects data in 1Q13 from a...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >